VYNE Therapeutics (VYNE) reports 20,000 stock options granted to director

Rhea-AI Filing Summary

VYNE Therapeutics Inc. reported that a non-employee director received an annual stock option award on December 12, 2025, the date of the company’s annual meeting of stockholders. The filing shows the grant of 20,000 stock options to purchase VYNE common stock at an exercise price of $0.3756 per share. These options vest on December 12, 2026, conditioned on the director’s continuous service through that date, and are scheduled to expire on December 11, 2035. Following this transaction, the director is shown as beneficially owning 20,000 derivative securities, all held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BARBARI SHARON

(Last) (First) (Middle)

C/O VYNE THERAPEUTICS INC.

P.O. BOX 125

(Street)

STEWARTSVILLE NJ 08886

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VYNE Therapeutics Inc. [ VYNE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.3756	12/12/2025		A		20,000		(1)	12/11/2035	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date.

	/s/ Mutya Harsch, Attorney-in-Fact	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did VYNE Therapeutics (VYNE) report in this Form 4?

The Form 4 reports that a non-employee director of VYNE Therapeutics Inc. received an annual award of 20,000 stock options on December 12, 2025.

How many stock options were granted to the VYNE director and at what exercise price?

The director was granted 20,000 stock options, each with an exercise price of $0.3756 per share of VYNE common stock.

When do the VYNE Therapeutics director stock options vest?

The options vest on December 12, 2026, and this vesting is subject to the reporting person’s continuous service with VYNE through that date.

What is the expiration date of the VYNE director’s stock options?

The stock options are scheduled to expire on December 11, 2035, as disclosed in the derivative securities table.

Is this stock option grant part of VYNE’s annual non-employee director compensation?

Yes. The explanation states that the grant represents the annual award to non-employee directors of VYNE, awarded on the date of the annual meeting of stockholders.

How many derivative securities does the VYNE director beneficially own after this transaction?

After the reported transaction, the director beneficially owns 20,000 derivative securities (stock options), held in direct ownership form.